Developing an Effective Peptide-Based Vaccine for COVID-19: Preliminary Studies in Mice Models

Area of Science:

• Immunology
• Vaccinology
• Molecular Biology

Background:

• Coronavirus disease 2019 (COVID-19) poses significant global health and economic challenges.
• Current vaccines offer protection but face uncertainties regarding long-term efficacy and effectiveness against emerging SARS-CoV-2 variants.

Purpose of the Study:

• To develop and evaluate a novel peptide-based vaccine for preventing COVID-19.
• To assess the immunogenicity and efficacy of the peptide vaccine in a preclinical mouse model.

Main Methods:

• Selection of 15 B cell epitopes from the SARS-CoV-2 spike protein with in silico HLA affinity prediction.
• Testing of peptide vaccines with QS21 or Al(OH)3 adjuvants in C57BL/6 mice.
• Evaluation of antibody and T cell responses, epitope mapping, and pseudoparticle neutralization assays.

Main Results:

• The peptide-based vaccine elicited robust and sustained antibody responses in mice.
• Adjuvant choice influenced T and B cell responses.
• Antibody profiles in vaccinated mice mimicked those of COVID-19 convalescent individuals.
• Vaccine-induced plasma demonstrated neutralizing activity against SARS-CoV-2.

Conclusions:

• The developed peptide-based vaccine generates durable and effective B and T cell responses.
• This vaccine strategy is adaptable for future SARS-CoV-2 variants.
• The approach holds potential as a safe and effective COVID-19 vaccine, minimizing autoimmune risks.